


We claim:

1. A compound of formula (I)



p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X_1 is CH_2 , CH , or N ; to form a indoliny, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;


X_2 is CH or N ;

R^1 and R^2 are independently selected from hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, phenyl, $\text{C}_1\text{-C}_{10}$ alkylaryl, SO_2R^8 , $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^8\text{R}^8$, $\text{SO}_2\text{C}_1\text{-C}_{10}$ alkylaryl, $\text{SO}_2\text{C}_1\text{-C}_8$ alkylheterocyclic, $\text{C}_4\text{-C}_{10}$ alkylcycloalkyl, $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^8$, and $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, phenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylaryl, and $\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl; and wherein R^1 and R^2 may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen -containing heterocycle may further have substituents selected from the group consisting of oxo, amino, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, phenyl, $\text{C}_1\text{-C}_3$ alkylaryl, $\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, $\text{CO}(\text{O})\text{C}_1\text{-C}_8$ alkyl, halo, $\text{C}_1\text{-C}_3$ haloalkyl; R^3 and $R^{3'}$ are each independently selected from hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, and $\text{C}_1\text{-C}_8$ alkylaryl; R^4 and R^5 are each independently selected from hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, $\text{C}_1\text{-C}_8$ alkoxy, halo, $\text{C}_1\text{-C}_8$ haloalkyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl, $(\text{CH}_2)_m\text{NSO}_2\text{C}_1\text{-C}_8$ alkyl, $(\text{CH}_2)_m\text{NSO}_2$ phenyl, $(\text{CH}_2)_m\text{NSO}_2$ aryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, and $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl; wherein each R^4 and R^5 is attached to its respective ring only at carbon atoms; wherein m is 1 or 2;

R^6 and R^7 are each independently selected from hydrogen, C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, $C(O)C_1$ - C_8 alkyl, SO_2C_1 - C_8 alkyl, SO_2C_1 - C_8 alkylaryl, SO_2C_1 - C_8 alkylheterocyclic, aryl, C_1 - C_8 alkylaryl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkylcycloalkyl, $(CH_2)_mC(O)OR^8$, $(CH_2)_mC(O)R^8$, $(CH_2)_mC(O)NR^8R^8$, and $(CH_2)_mNSO_2R^8$; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C_1 - C_8 alkyl, C_2 - C_8 alkenyl, phenyl, and C_1 - C_8 alkylaryl; and wherein R^6 and R^7 may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino, C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, phenyl, and C_1 - C_8 alkylaryl;

R^8 is independently selected from hydrogen, C_1 - C_8 alkyl, C_2 - C_8 alkenyl, phenyl, benzyl, and C_5 - C_8 alkylaryl; or a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

2. A compound of formula II



wherein p is 0, 1, or 2;

y is 0, 1, or 2; and z is 0, 1, or 2;

X_1 is CH_2 , CH , or N ; to form a indolinyl, indolyl, or benzimidazole ring respectively and including applicable double bonds and/or hydrogen atoms;

X_2 is CH or N ;


R^1 and R^2 are independently selected from hydrogen, C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, phenyl, C_1 - C_{10} alkylaryl, SO_2R^8 , $(CH_2)_nC(O)NR^8R^8$, SO_2C_1 - C_{10} alkylaryl,

SO₂C₁-C₈ alkylheterocyclic, C₄-C₁₀ alkylcycloalkyl, (CH₂)_nC(O)OR⁸, and (CH₂)_nC(O)R⁸; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, C₃-C₈ cycloalkyl, C₁-C₈ alkylaryl, and C(O)C₁-C₈ alkyl; and wherein R¹ and R² may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of oxo, amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, C₁-C₃ alkylaryl, C(O)C₁-C₈ alkyl, CO(O)C₁-C₈ alkyl, halo, C₁-C₃ haloalkyl; R³ and R^{3'} are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, aryl, C₁-C₈ alkylcycloalkyl, and C₁-C₈ alkylaryl; R⁴ and R⁵ are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₁-C₈ alkoxy, halo, C₁-C₈ haloalkyl, phenyl, aryl, C₁-C₈ alkylaryl, (CH₂)_mNSO₂C₁-C₈ alkyl, (CH₂)_mNSO₂phenyl, (CH₂)_mNSO₂aryl, -C(O)C₁-C₈ alkyl, and -C(O)OC₁-C₈ alkyl; wherein each R⁴ and R⁵ is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3; R⁶ and R⁷ are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C(O)C₁-C₈ alkyl, SO₂C₁-C₈ alkyl, SO₂C₁-C₈ alkylaryl, SO₂C₁-C₈ alkylheterocyclic, C₁-C₈ alkylaryl, C₃-C₇ cycloalkyl, C₁-C₆ alkylcycloalkyl, aryl, (CH₂)_mC(O)OR⁸, (CH₂)_mC(O)R⁸, (CH₂)_mC(O)NR⁸R⁸, and (CH₂)_mNSO₂R⁸; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, and C₁-C₈ alkylaryl; and wherein R⁶ and R⁷ may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, and C₁-C₈ alkylaryl; R⁸ is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, benzyl, and C₅-C₈ alkylaryl; or a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

3. A compound according to Claim 1 wherein X₁ is CH and X₂ is selected CH.

4. A compound according to Claim 1 wherein X_1 is CH and X_2 is selected N.
5. A compound according to Claim 1 wherein X_1 is N, and X_2 is CH.
6. A compound according to Claim 1 wherein X_1 is N, and X_2 is N.
7. A compound according to Claim 1 wherein y is 0 or 1, and R^4 is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.
8. A compound according to Claim 1 wherein z is 0 or 1, and R^5 is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.
9. A compound according to Claim 2 wherein X_1 is CH and X_2 is selected CH.
10. A compound according to Claim 2 wherein X_1 is CH and X_2 is selected N.
11. A compound according to Claim 2 wherein X_1 is N, and X_2 is CH.
12. A compound according to Claim 2 wherein X_1 is N, and X_2 is N.
13. A compound according to Claim 2 wherein y is 0 or 1, and R^4 is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.
14. A compound according to Claim 2 wherein z is 0 or 1, and R^5 is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

15. A compound according to Claim 1 or 2 wherein R¹ and R² are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,



16. The compound according to Claim 1 or 2 wherein R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and phenyl.

17. A compound selected from the group consisting of:

- 4-{ 5-[(3-Methyl-butylamino)-methyl]-indol-1-ylmethyl }-benzamide,
4-{ 5-[(2-Thiophen-2-yl-ethylamino)-methyl]-indol-1-ylmethyl }-benzamide,
4-{ 5-[(3,3-Dimethyl-butylamino)-methyl]-indol-1-ylmethyl }-benzamide,
4-{ 5-[(2-Thiophen-2-yl-ethylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl }-benzamide,
4-{ 5-[(3-Methyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl }-benzamide,
4-{ 5-[(3,3-Dimethyl-butylamino)-methyl]-2,3-dihydro-indol-1-ylmethyl }-benzamide,
4-(5-Hexylaminomethyl-indol-1-ylmethyl)-benzamide,
4-{ 5-[(3-Phenyl-propylamino)-methyl]-indol-1-ylmethyl }-benzamide,
4-(5-{ [2-(2-Fluoro-phenyl)-ethylamino]-methyl }-indol-1-ylmethyl)-benzamide,
4-{ 5-[(2-Hydroxy-ethylamino)-methyl]-indol-1-ylmethyl }-benzamide,
4-(5-{ [2-(4-Methoxy-phenyl)-ethylamino]-methyl }-indol-1-ylmethyl)-benzamide,
4-{ 5-[(2-Chloro-6-fluoro-benzylamino)-methyl]-indol-1-ylmethyl }-benzamide,

4-{5-[(2-Pyridin-3-yl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(2-Ethoxy-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-(5-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Cyclohex-1-enyl-ethylamino)-methyl]-indol-1-ylmethyl}-benzamide,
4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-indol-1-ylmethyl)-benzamide,
4-{5-[(2-Ethyl-butylamino)-methyl]-indol-1-ylmethyl}-benzamide,
1-{4-[(3-Methyl-butylamino)-methyl]-benzyl}-2,3-dihydro-1H-indole-5-carboxylic acid
amide or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and
diastereomeric mixture thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof in association with a carrier, diluent and/or excipient.

18. A method for blocking a mu, kappa, delta or receptor combination (heterodimer) thereof in mammals comprising administering to a mammal requiring blocking of a mu, kappa, delta or receptor combination (heterodimer) thereof, a receptor blocking dose of a compound of formula I or II or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomeric mixture thereof.

19. A method of treating or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II.

20. A method according to Claim 19 wherein the Related Diseases is selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy, atherosclerosis, hyperlipidemia, hypertriglyceremia, hyperglycemia, and hyperlipoproteinemia.

21. A method of treating and/or preventing diseases related to obesity including irritable bowel syndrome, nausea, vomiting, depression, smoking and alcohol

addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors, and stroke comprising administering a therapeutically effective amount of a compound of formula I or II.

22. A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of formula I or II.

23. Use of a compound of formula I or II in the manufacture of a medicament for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I or II to a patient in need thereof.